A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Trial details
- Registry ID
- NCT07271667
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as CA-4948
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesNCT07271667 | CRIS | Phase 2 | Recruiting | 2027-11Estimated |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)NCT03328078 | CRIS | Phase 1, Phase 2 | Recruiting | 2027-07Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |